<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144079</url>
  </required_header>
  <id_info>
    <org_study_id>MSDS</org_study_id>
    <secondary_id>Deutsche Krebshilfe 70-2294</secondary_id>
    <nct_id>NCT00144079</nct_id>
  </id_info>
  <brief_title>Multicenter Study Differentiated Thyroid Carcinoma</brief_title>
  <official_title>Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <brief_summary>
    <textblock>
      The trial examines the clinical benefit of adjuvant external beam radiotherapy (RTx) for&#xD;
      locally invasive differentiated carcinoma (TNM stages pT4 pN0/1/x M0/x; 5th ed. 1997) of the&#xD;
      thyroid gland (DTC). Patients are treated with surgery (thyroidectomy and lymphadenectomy),&#xD;
      radioiodine therapy (RIT) to ablate the thyroid remnant tissue, and TSH-suppressive&#xD;
      L-thyroxine therapy with or without RTx after documented elimination of cervical I-131&#xD;
      uptake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MSDS was designed as a comprehensive cohort trial with randomization and observation arms.&#xD;
      Patients are enrolled at the time of the first ablative radioiodine therapy (RIT). Inclusion&#xD;
      criteria are papillary or follicular DTC pT4 pN0/1/x M0/x, age between 18 (incl.) and 70&#xD;
      years (excl.) at the time of initial surgery, completion of primary surgical therapy with R0&#xD;
      (no tumor residues) or R1 (microscopic residues) resection, Karnofsky index of at least 70 %,&#xD;
      freedom from distant metastases at the time of initial radioiodine therapy (RIT), and&#xD;
      informed patient consent. Criteria for exclusion are secondary malignancy except basalioma,&#xD;
      pregnancy, serious general disease, serious psychiatric disorder, inability to give informed&#xD;
      consent, previous RTx and recurrence of previous DTC. From 2003, the first inclusion&#xD;
      criterion was changed into DTC pT3/4 pN0/1/x M0/x to reflect the 2002 revision of the TNM&#xD;
      staging system.&#xD;
&#xD;
      The treatment protocol is in accordance with current guidelines in Germany and includes total&#xD;
      thyroidectomy (TT) with central lymphadenectomy (LNA), RIT to ablate the thyroid remnant, and&#xD;
      TSH-suppressive therapy with L-thyroxine (TSH &lt; 0.1 mU/l). RIT is administered under&#xD;
      endogenous TSH-stimulation after 4 weeks' cessation of L-thyroxine using standard activities&#xD;
      of 1-4, and 1-2, GBq I-131 in patients with a 24-h-I-131 uptake below 10 % and 10-20 %,&#xD;
      resp., or individual dosimetry aiming for at least 300 Gy in the thyroid remnant. If&#xD;
      scintigraphic I-131 uptake by the thyroid remnant persists at whole-body scintigraphy (at&#xD;
      least 200 MBq; at least 48 h) 3 months after RIT, a second fraction of RIT is given with 4-10&#xD;
      GBq.&#xD;
&#xD;
      Patients who consented to randomization at centers actively taking part in randomization were&#xD;
      randomized to treatment arms A (additional adjuvant RTx) and B (no RTx) 3 months after&#xD;
      initial RIT after confirmation of the histological diagnosis by the reference pathologist and&#xD;
      when distant metastases had been excluded by means of serum thyroglobulin (Tg), WBS (s. a.)&#xD;
      and a native thoracic computed tomogram (CCT). Randomization was stratified according to&#xD;
      histological type (papillary v. follicular), nodal status (pN0/1/x), and participating&#xD;
      center, and performed by an operator-independent randomization routine embedded in the&#xD;
      database. The remaining patients were assigned to arms A and B by the participating centers.&#xD;
&#xD;
      RTx is begun after documented elimination of cervical I-131 uptake in a I-131 WBS 3 months&#xD;
      after the last fraction of ablative RIT. RT includes the thyroid bed (in unilateral tumors&#xD;
      only the affected side) with a dose of 59.4 Gy and 66.6 Gy after R0 and R1 resection, resp.,&#xD;
      and the regional lymph nodes of the neck and upper mediastinum including the posterior&#xD;
      cervical chain from the mandible and mastoid process to the tracheal bifurcation with a dose&#xD;
      of 50.4 Gy and 54.0 Gy in pN0 and pN1/x disease, resp. Fractionation is conventional (1.8&#xD;
      Gy/d 5 days a week). 3-D planning according to IRCU 50 is mandatory.&#xD;
&#xD;
      Patient follow-up includes, as a minimum, out-patient appointments with cervical ultrasound&#xD;
      and measurement of serum TSH, hTG, anti-Tg antibodies and a blood count 2 and 8 months after&#xD;
      each RIT or WBS, and a WBS (with at least 200 MBq over at least 48 h) under endogenous&#xD;
      TSH-stimulation 3 and 12 months after ablative RIT and then at 24-month intervals. FDG-PET&#xD;
      and other imaging modalities can be performed if needed. At each follow-up appointment, RTx&#xD;
      toxicity is recorded according to RTOG criteria and quality of life by the QLQ-C30&#xD;
      questionnaire (v. 3.0 German) of the EORTC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date>January 2010</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to local or distant failure</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>cancer-related mortality</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute toxicity of radiotherapy (RTOG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic toxicity of radiotherapy (RTOG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Thyroid Neoplasms</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>external beam radiotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  papillary or follicular thyroid carcinoma pT4 pN0/1/x M0/x&#xD;
&#xD;
          -  completion of primary surgical therapy with R0 (no tumor residues) or R1 (microscopic&#xD;
             residues) resection&#xD;
&#xD;
          -  Karnofsky index &gt; 70 %&#xD;
&#xD;
          -  freedom from distant metastases at the time of initial radioiodine therapy&#xD;
&#xD;
          -  informed patient consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary malignancy except basalioma&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  serious general disease&#xD;
&#xD;
          -  serious psychiatric disorder&#xD;
&#xD;
          -  inability to give informed consent&#xD;
&#xD;
          -  previous RTx&#xD;
&#xD;
          -  recurrence of previous thyroid cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otmar Schober, Prof MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nuclear Medicine, Münster University Hospital, Münster, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henning Dralle, Prof MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of General Surgery, University Halle-Wittenberg, Halle, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Normann Willich, Prof MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Radiooncology, Münster University Hospital, Münster, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Biermann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Nuclear Medicine, Münster University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Burkhard Riemann, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Nuclear Medicine, Münster University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Schuck, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Radiooncology, Münster University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nuclear Medicine</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Wien University Hospital</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, University Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear medicine, Saarland University</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Cologne University</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Münster University Hospital</name>
      <address>
        <city>Münster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Katharinen-Hospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Helios-Klinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>44283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Würzburg University</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Zürich University Hospital</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://nuklearmedizin.uni-muenster.de</url>
    <description>Home page of the Department of Nuclear Medicine at Münster University Hospital</description>
  </link>
  <reference>
    <citation>Puskás C, Schober O. [Adjuvant percutaneous radiation of locally advanced papillary and follicular thyroid carcinoma: reflections for the necessity of a prospective multicenter study]. Nuklearmedizin. 1999;38(8):328-32. Review. German.</citation>
    <PMID>10615667</PMID>
  </reference>
  <reference>
    <citation>Biermann M, Schober O; Multizentrische Studie Differenziertes Schilddrüsenkarzinom Studiengruppe. [How many high-risk patients with differentiated thyroid cancer need a &quot;Tumor Center&quot; per year?]. Nuklearmedizin. 2002 Apr;41(2):61-2. German.</citation>
    <PMID>11989299</PMID>
  </reference>
  <reference>
    <citation>Biermann M, Schober O. GCP-compliant management of the Multicentric Study Differentiated Thyroid Carcinoma (MSDS) with a relational database under Oracle 8i. Inform Biom Epidemiol Med Biol 33:441-59, 2002</citation>
  </reference>
  <reference>
    <citation>Biermann M, Pixberg M, Schuck A, Willich N, Heinecke A, Schober O. External beam radiotherapy. An evidence-based review. In: Biersack H-J, Grünwald F, eds. Thyroid cancer. Heidelberg: Springer; 139-61, 2005.</citation>
  </reference>
  <results_reference>
    <citation>Biermann M, Pixberg MK, Schuck A, Heinecke A, Köpcke W, Schmid KW, Dralle H, Willich N, Schober O. Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin. 2003 Dec;42(6):244-50.</citation>
    <PMID>14668957</PMID>
  </results_reference>
  <results_reference>
    <citation>Schuck A, Biermann M, Pixberg MK, Müller SB, Heinecke A, Schober O, Willich N. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). Strahlenther Onkol. 2003 Dec;179(12):832-9.</citation>
    <PMID>14652672</PMID>
  </results_reference>
  <results_reference>
    <citation>Biermann M, Pixberg MK, Dörr U, Dietlein M, Schlemmer H, Grimm J, Zajic T, Nestle U, Ladner S, Sepehr-Rezai S, Rosenbaum S, Puskás C, Fostitsch P, Heinecke A, Schuck A, Willich N, Schmid KW, Dralle H, Schober O; MSDS study group. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice. Nuklearmedizin. 2005;44(6):229-34, 236-7.</citation>
    <PMID>16400382</PMID>
  </results_reference>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>May 8, 2006</last_update_submitted>
  <last_update_submitted_qc>May 8, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2006</last_update_posted>
  <keyword>Differentiated thyroid carcinoma</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>radioiodine therapy</keyword>
  <keyword>thyroidectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

